2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Imaging, Omics Technologies, Bioinformatics, Cell Expansion, Computational Biology, Biological Processes, Genomics, Hematopoiesis, Immune Mechanism, Metabolism, Molecular Biology, Diseases, Myeloid Malignancies, Chronic Myeloid Malignancies, Research, Fundamental Science, Translational Research, Study Population, Human, Animal Model
PAPER

1361 Measuring AP-1 activity in an age-associated subset of human hematopoietic stem cells

Basit Salik, PhD, Ksenia Safina, PhD2, Jonathan D Good3, Hanna Frieß4, Peter van Galen, PhD5
1 Broad Institute of MIT and Harvard, Cambridge, Massachusetts, United States, Department of Medicine, Harvard Medical School, Boston, Massachusetts, United States, Division of Hematology, Brigham and Women's Hospital, Boston, Massachusetts, United States, Ludwig Center at Harvard, Boston, Massachusetts, United States
2 Broad Institute of MIT and Harvard, Cambridge, Massachusetts, United States, Department of Medicine, Harvard Medical School, Boston, Massachusetts, United States, Division of Hematology, Brigham and Women's Hospital, Boston, Massachusetts, United States, Ludwig Center at Harvard, Boston, Massachusetts, United States
3 Broad Institute of MIT and Harvard, Cambridge, Massachusetts, United States, Department of Medicine, Harvard Medical School, Boston, Massachusetts, United States, Division of Hematology, Brigham and Women's Hospital, Boston, Massachusetts, United States, Ludwig Center at Harvard, Boston, Massachusetts, United States
4 Broad Institute of MIT and Harvard, Cambridge, Massachusetts, United States, Department of Medicine, Harvard Medical School, Boston, Massachusetts, United States, Division of Hematology, Brigham and Women's Hospital, Boston, Massachusetts, United States, Ludwig Center at Harvard, Boston, Massachusetts, United States
5 Broad Institute of MIT and Harvard, Cambridge, Massachusetts, United States, Department of Medicine, Harvard Medical School, Boston, Massachusetts, United States, Division of Hematology, Brigham and Women's Hospital, Boston, Massachusetts, United States, Harvard Stem Cell Institute, Cambridge, Massachusetts, United States, Ludwig Center at Harvard, Boston, Massachusetts, United States

Background: The hematopoietic system undergoes remodeling with age. Single-cell transplantation and, more recently, single-cell sequencing studies have established that hematopoietic stem cells (HSCs) are molecularly heterogeneous and comprise distinct inflammatory states with age-dependent distributions. We reported that AP-1 transcription factors mark an inflammatory and quiescent human HSC subpopulation that expands with age. This subset appears distinct from conventional HSCs, yet we lack tools to prospectively isolate and functionally characterize these cells.

Methods: To prospectively isolate HSCs based on AP-1 activity, we developed a dual-color bidirectional lentiviral AP-1 reporter incorporating tandem AP-1 response elements upstream of GFP, with constitutive mCherry marking transduced cells. The reporter was validated in CD34+ MUTZ-3 cells using a panel of inflammatory stimuli including PMA and TNF-α. To define the transcriptional state associated with reporter activity, AP-1high (GFPbright) and AP-1low (GFPdim) CD34+ MUTZ-3 fractions were FACS-sorted from four replicate cultures and profiled by bulk RNA-seq. Differential expression was assessed with DESeq2 using a paired design (~ replicate + condition), and pathway enrichment by GSEA with genes ranked by log2 fold change and Benjamini-Hochberg correction across all gene sets tested. We also optimized an intracellular flow cytometry protocol to detect phosphorylated c-JUN (Ser63) in CD34+CD38- HSCs from cryopreserved human bone marrow samples. These were obtained from young and aged donors through our IRB-approved biobank and from commercially available sources.

Results: Our prior work identified an AP-1-active HSC population at the transcriptional level. Intracellular flow cytometry confirmed elevated phosphorylation of the AP-1 transcription factor c-JUN at serine 63, an activating post-translational modification, in a distinct CD34+CD38- HSC-enriched population. Notably, pooled analysis across two independent experiments showed that this population constituted a larger proportion of HSCs in aged (n=9, aged 76-89 years, 11.26±2.3%) than in young donors (n=8, aged 23-35 years, 1.89±0.8%, P=0.0025). We validated the dual-color AP-1 reporter in CD34+ MUTZ-3 leukemia cells using three complementary approaches. First, intracellular phospho-c-JUN staining correlated with GFP fluorescence. Second, PMA and TNF-α reproducibly activated the AP-1 reporter whereas IL-1β, IL-6, TGF-β, IFN-α and IFN-γ showed minimal or no reporter activation. Third, we FACS-sorted AP-1high (GFPbright) and AP-1low (GFPdim) CD34+ MUTZ-3 fractions and profiled their transcriptomes by RNA-seq. Paired differential expression analysis identified 720 differentially expressed genes (FDR < 0.05). Gene set enrichment analysis using 50 MSigDB Hallmark gene sets together with curated AP-1 target gene sets showed enrichment of inflammatory transcriptional programs in GFPbright cells, including inflammatory response (NES = 1.93, FDR = 4.5 × 10⁻⁷) and TNF-α signaling via NF-κB (NES = 1.91, FDR = 4.3 × 10⁻⁸) pathways together with Matthews AP-1 targets (NES = 1.86, FDR = 9.2 × 10⁻⁴) and the PID AP-1 pathway (NES = 1.73, FDR = 0.012). These findings indicate that AP-1 reporter activity can identify cells with a coordinated inflammatory transcriptional state.

Conclusions: Here, we established tools to identify AP-1-active HSCs, a population that makes up a larger proportion of HSCs in aged compared to young donors. Our dual-color reporter enables prospective isolation of AP-1-active cells. Future experiments will assess functional properties of HSC subsets isolated using the reporter through xenotransplantation to determine whether AP-1-active HSCs exhibit altered differentiation, proliferation, or reconstitution potential. These tools may help define age-associated HSC states and reveal therapeutic targets for regulating inflammation in the aging hematopoietic system.

Basit Salik, PhD: No relevant conflicts of interest to declare.